Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OSI Pharmaceuticals, a biotechnology company, has filed two lawsuits in US District Court in Delaware against Teva Pharmaceuticals USA, and Mylan Pharmaceuticals, a generic pharmaceutical company, for infringement of three US patents associated with Tarceva.
Subscribe to our email newsletter
The lawsuits are based on abbreviated new drug applications (ANDA) filed by Teva and Mylan seeking permission to manufacture and market a generic version of Tarceva before the expiration of the three patents.
The filing of these lawsuits restricts the FDA from approving Teva and Mylan’s ANDAs until May 18, 2012, unless an adverse court ruling occurs prior to such time. OSI plans to vigorously protect and enforce the intellectual property rights of Tarceva.